EP
GYRE icon

Essential Partners’s Gyre Therapeutics GYRE Stock Holding History

Essential Partners’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7 Sell
1
-3
-75% -$20 ﹤0.01% 2850
2026
Q1 		$28 Buy
+4
New +$31 ﹤0.01% 2812
2025
Q3 		– Sell
-2
Closed -$15 – 2716
2025
Q2 		$15 Buy
+2
New +$17 ﹤0.01% 2237

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Essential Partners's GYRE Position: Q2 2026 in Review

Essential Partners reduced its Gyre Therapeutics (GYRE) stake by 75% in Q2 2026, selling an estimated $20 and leaving 1 share worth $7. The position accounts for ﹤0.01% of the portfolio, ranked #2850.

Essential Partners first reported a position in GYRE in Q2 2025 and has held it in 3 quarters since. The position peaked at $28 in Q1 2026. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • Essential Partners held 1 share of Gyre Therapeutics worth $7 as of Q2 2026.
  • Essential Partners sold 3 Gyre Therapeutics shares in Q2 2026, an estimated $20.
  • Gyre Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2850 holding.
  • Essential Partners first reported a position in Gyre Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Essential Partners's Gyre Therapeutics position peaked at $28 in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.